Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors

被引：0
|
作者：
Henshaw, Joshua W. [1 ]
Zhou, Huiyu [1 ]
Herriott, Ashleigh [2 ]
Patterson, Miranda [2 ]
Wang, Evelyn W. [1 ]
Musson, Don [1 ]
de Bono, Johann [3 ]
Mina, Lida A. [4 ]
Ramanathan, Ramesh K. [5 ]
O'Neill, Charles [1 ]
Dorr, Andrew [1 ]
Curtin, Nicola J. [2 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
[2] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[4] Indiana Univ, Indianapolis, IN 46204 USA
[5] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-A220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A220
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
    Wainberg, Zev A.
    de Bono, Johann S.
    Mina, Lida
    Sachdev, Jasgit
    Byers, Lauren Averett
    Chugh, Rashmi
    Zhang, Charlie
    Henshaw, Joshua W.
    Dorr, Andrew
    Glaspy, John
    Ramanathan, Ramesh
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [2] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations
    Meehan, Robert S.
    Chen, Alice P.
    Coyne, Geraldine O'Sullivan
    Kummar, Shivaani
    Ji, Jiuping
    Vilimas, Rasa
    Juwara, Lamin
    Kinders, Robert J.
    Ferry-Galow, Katherine
    Wilsker, Deborah
    Zhang, Yiping
    Dull, Angie B.
    Navas, Tony
    Wang, Lihua
    Parchment, Ralph E.
    Doroshow, James H.
    CANCER RESEARCH, 2017, 77
  • [4] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
    Arjun Mittra
    Geraldine H. O’ Sullivan Coyne
    Jennifer Zlott
    Shivaani Kummar
    Robert Meehan
    Lawrence Rubinstein
    Lamin Juwara
    Deborah Wilsker
    Jiuping Ji
    Brandon Miller
    Tony Navas
    Katherine V. Ferry-Galow
    Andrea Regier Voth
    Ting-Chia Chang
    Shahanawaz Jiwani
    Ralph E. Parchment
    James H. Doroshow
    Alice P. Chen
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 177 - 189
  • [5] Population Pharmacokinetics of BMN 673, a Novel PARP Inhibitor, in Beagle Dogs
    Qi, Yulan
    Musson, Don
    Tsuruda, Laurie
    Zhou, Huiyu
    Cheng, Alphonsus
    O'Neill, Charles
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S30 - S30
  • [6] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
    Mittra, Arjun
    Coyne, Geraldine H. O' Sullivan
    Zlott, Jennifer
    Kummar, Shivaani
    Meehan, Robert
    Rubinstein, Lawrence
    Juwara, Lamin
    Wilsker, Deborah
    Ji, Jiuping
    Miller, Brandon
    Navas, Tony
    Ferry-Galow, Katherine V.
    Voth, Andrea Regier
    Chang, Ting-Chia
    Jiwani, Shahanawaz
    Parchment, Ralph E.
    Doroshow, James H.
    Chen, Alice P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (03) : 177 - 189
  • [7] PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
    Herriott, Ashleigh
    Tudhope, Susan J.
    Junge, Gesa
    Rodrigues, Natalie
    Patterson, Miranda J.
    Woodhouse, Laura
    Lunec, John
    Hunter, Jill E.
    Mulligan, Evan A.
    Cole, Michael
    Allinson, Lisa M.
    Wallis, Jonathan P.
    Marshall, Scott
    Wang, Evelyn
    Curtin, Nicola J.
    Willmore, Elaine
    ONCOTARGET, 2015, 6 (41) : 43978 - 43991
  • [8] RESULTS OF A PHASE 1 STUDY OF BMN 673, A POTENT AND SPECIFIC PARP-1/2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES
    Mufti, G. J.
    Estey, E.
    Popat, R.
    Mattison, R.
    Menne, T.
    Azar, J.
    Bloor, A.
    Gaymes, T.
    Khwaja, A.
    Juckett, M.
    Lennard, A.
    Zhang, C.
    Gallant, G. J. A.
    Gopal, A. K.
    HAEMATOLOGICA, 2014, 99 : 33 - 34
  • [9] The effect of food on the oral bioavailability of the novel PARP 1/2 inhibitor BMN 673 in healthy male subjects
    Henshaw, Joshua
    Zhou, Huiyu
    Musson, Don
    O'Neill, Charles
    Stoltz, Randall
    Dorr, Andrew
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer
    Yin, Yuping
    Shen, Qian
    Zhang, Peng
    Tao, Ruikang
    Chang, Weilong
    Li, Ruidong
    Xie, Gengchen
    Liu, Weizhen
    Zhang, Lihong
    Kapoor, Prabodh
    Song, Shumei
    Ajani, Jaffer
    Mills, Gordon B.
    Chen, Jianying
    Tao, Kaixiong
    Peng, Guang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (03): : 473 - 483
12345